For patients with persistently high disease activity despite conventional treatment, the most recent 2022 recommendations by the Assessment of SpondyloArthritis International Society (ASAS) and the European Alliance of Associations for Rheumatology (EULAR) suggest considering tumor necrosis factor (TNF) inhibitors, interleukin 17 (IL-17) inhibitors, or Janus kinase (JAK) inhibitors [3]. This evidence concerns the gene IL17A and spondyloarthropathy.